Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The Food and Drug Administration released documents detailing Moderna's coronavirus vaccine candidate's "favorable safety profile" on Tuesday ahead of a key committee meeting scheduled for Thursday.

Moderna COVID-19 vaccine has 'favorable safety profile,' FDA documents show, putting it closer to approval

Shares of Moderna Inc. gained 1.5% in premarket trading on Tuesday after the Food and Drug Administration said the company's COVID-19 vaccine candidate is "highly effective" at preventing infections with the coronavirus. The regulator on Tuesday morning published a document outlining its thinking about Moderna's emergency use application in advance of the FDA Vaccines and Related Biological Products Advisory Committee's scheduled meeting on Thursday.

Moderna's shares are up as FDA says COVID-19 vaccine is 'highly effective'

Moderna's vaccine could be administered to the public as early as next week if it wins emergency use authorization from the FDA.

FDA staff report backs emergency use of Moderna's Covid vaccine in a critical step toward approval

The feds are reportedly slated to release detailed data about Moderna's coronavirus vaccine on Tuesday ahead of a key vote to clear a second shot for emergency use.

FDA to release data on Moderna COVID-19 vaccine ahead of key vote

The US plans to ship 6 million doses of Moderna's COVID-19 vaccine as soon as the Food and Drug Administration (FDA) authorizes it for emergency use, officials said Monday — more than double the nation's initial shipment of Pfizer's shot. This approval is "likely" to come by as Friday, the head of the White House's vaccine effort said Sunday. A panel of FDA experts will review the vaccine Thursday.

The US will ship 6 million doses of Moderna's COVID-19 vaccine straight after the FDA authorizes it — double its initial shipment of Pfizer's shot

BioNTech SE

Celldex Therapeutics

Co-Diagnostics

Cardiff Oncology

Seres Therapeutics

Nestle SA

Novavax

Trillium Therapeutics

Vaxart

The highest performers of the year are biotechs fighting COVID-19 and cancer. Are they still buys for 2021?

These Were the 10 Best Healthcare Stocks of 2020

An FDA meeting this week will be crucial for this coronavirus vaccine maker.

Why Is Everyone Talking About Moderna Stock?

Pfizer

Which Is the Best COVID Vaccine Stock Now: Pfizer, BioNTech, or Moderna?

Moderna Inc (NASDAQ: MRNA) said documents related to its COVID-19 vaccine were targeted by hackers in an attack on the European Medicines Agency (EMA), Reuters reported Monday. What Happened: The Cambridge, Massachusetts-based vaccine maker said its submissions to the EMA didn't contain any information pertaining to the identity of its vaccine study participants.

After Pfizer, Moderna's COVID-19 Vaccine Data Comprised In Cyberattack

Moderna Inc said on Monday it was informed by the European Medicines Agency (EMA) certain documents related to pre-submission talks of its COVID-19 vaccine candidate were unlawfully accessed in a cyberattack on the medicines regulator.

Moderna COVID-19 vaccine documents accessed in EMA cyberattack

U.S. officials said they plan to ship just under 6 million doses of Moderna's Covid-19 vaccine once the FDA issues an approval for emergency use.

U.S. plans to ship 6 million Moderna Covid vaccine doses once FDA gives OK as early as week's end

A Food and Drug Administration advisory committee will meet for the second time in a week to discuss whether the regulator should authorize Moderna Inc.'s COVID-19 vaccine candidate. The same committee, the Vaccines and Related Biological Products Advisory Committee, met Dec. 10 and voted 17-4-1 that the FDA should grant an emergency use authorization to BioNTech and Pfizer Inc.'s COVID-19 vaccine.

FDA committee to meet again Thursday for Moderna's COVID-19 vaccine

Merck

The big drugmaker did something many investors do.

Here's Why Merck Made a Mistake by Selling Its Moderna Stake

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna confirms supply agreement with the Ministry of Health to supply Singapore with mRNA vaccine against COVID-19 (mRNA-1273).

Moderna Confirms Supply Agreement with the Ministry of Health to Supply Singapore with mRNA Vaccine Against COVID-19 (mRNA-1273)

US drugmakers Pfizer and Moderna could rake in around $32 billion in revenues from their COVID-19 vaccines in 2021, according to Wall Street estimates. Pfizer and its German partner BioNTech will bring in roughly $19 billion from global sales of its COVID-19 vaccine in 2021, according to Morgan Stanley estimates first reported by CNN on Friday.

Pfizer and Moderna could earn $32 billion in revenues from their COVID-19 vaccines in 2021

Salesforce

CrowdStrike

Renaissance IPO ETF

Okta

Palo Alto Networks

Pinterest

Snap

Uber

Zoom Video

Sticking with my theme of trading in ETFs that offer exposure to unique investment niches, the IPO fund is next on my radar.

Riding The Wave Of IPO Mania

More than just a rosy outlook for the COVID vaccine is priced into the shares.

Buy, Sell, or Hold Moderna Stock at an All-Time High?

Hint: It's a big number -- but not nearly big enough.

How Many COVID Vaccine Doses Will Pfizer and Moderna Distribute by Year-End?

Not all sales are done because the investor thinks a stock is overvalued.

Why Did This Big Investor Sell Its Moderna Stock?

Arcturus Therapeutics

Johnson & Johnson

Whether you're aggressive, risk-averse, or somewhere in between, here are some coronavirus vaccine stocks you might want to consider.

COVID Vaccine Stock Ideas for Different Investors

CVS Health

Walgreens

How Soon Will COVID Vaccines Be Available After FDA Authorization?

This as-of-now unstoppable COVID-19 stock might be one of the worst investments going forward.

The Most Popular Coronavirus Stock May Lose Half Its Value by 2023

Even as emergency use authorization came in late Friday for the COVID-19 vaccine from Pfizer Inc. (NYSE: PFE) and BioNTech SE – ADR (NASDAQ: BNTX), Moderna Inc (NASDAQ: MRNA) announced a greater committment from the U.S. for its vaccine candidate, mRNA-1273. What Happened: Cambridge, Massachusetts-based Moderna said the U.S. government has exercised an option to purchase an additional 100 million doses of mRNA-1273.

Moderna Says U.S. Has Committed To Another 100M Doses of COVID-19 Vaccine

The market's mood changes on a dime, but your position in a stock doesn't have to.

Moderna Investors, Meet Mr. Market

The new order doubles the country's original commitment.

News for Moderna Stock (MRNA)